1 Patients had to be 18 years or older with a confirmed FMD dia
2 urrent psychotic episode had to be 5 or fewer years, and 2)
patients had to be 45 years of age or younger at onset of fir
3 Patients had to be admitted for COVID-19 pneumonia within 7 d
4 Patients had to be aged 18 years or older and had to have a c
5 3 trial conducted at 227 clinical sites globally, enrolled
patients had to be aged 18 years or older with HER2-positive
6 Patients had to be aged 18 years or older, have an Eastern Co
7 Eligible
patients had to be aged 3-65 years, and to have NF1 and a cli
8 To be eligible,
patients had to be aged 50 years or older with non-centrepoin
9 Patients had to be aged 60 years or older, have aneurysms of
10 Eligible
patients had to be aged 65 years or older, have age-related m
11 To be eligible,
patients had to be aged at least 18 years and have a two-laye
12 Solely due to their death, 16
patients had to be classified as type C fistula, even though
13 For outcome assessment in the postdiscontinuation period,
patients had to be continuously enrolled in Medicaid for 6 mo
14 Hospitalized
patients had to be discharged alive and were then followed fo
15 Patients had to be discharged within 24 hours of triage and t
16 COVID-19
patients had to be fully recovered from COVID-19 pneumonia an
17 Patients had to be &
gt; or = 65 years of age, have established c
18 Patients had to be in full or partial remission from depressi
19 Patients had to be in good health, have sufficient bone to en
20 Patients had to be mechanically ventilated for more than 4 ho
21 Eligible
patients had to be positive for C trachomatis or C pneumoniae
22 Morbidity rate was 32.3%, 9
patients had to be reoperated.
23 In the case cohort 9/10
patients had to be treated with insulin for 1-26 days (range
24 MMF was well tolerated and no
patients had to be withdrawn as a result of medication toxici
25 Eligible
patients had to be younger than 6 months and have spinal musc